Log inStart free trialBook a demo
Book a demoLog inStart free trial
Media Database
>
Mark Leiser

Mark Leiser

Author at healio.com at Healio

Contact this person
Email address
m*****@*******.comGet email address
Influence score
26
Location
United States
Languages
  • English
Covering topics

    View more media outlets and journalists by signing up to Prowly

    View latest data and reach out all from one place
    Sign up for free

    Recent Articles

    healio.com

    Discussion about NIH research funding cuts requires 'data, time and careful evaluation'

    NIH’s plan to cut what it pays universities and other entities for indirect costs associated with scientific research would create “extremely challenging” short- and long-term impacts, according to a renowned data scientist and researcher.“If this comes to fruition, we’d be in a situation where we wouldn’t be able to do research the way we do it today,”
    about 2 months ago
    healio.com

    Research community braces for 'profoundly negative impact' of NIH cuts

    NIH’s decision to cut what it pays universities and other entities for indirect costs associated with scientific research would have immediate and far-reaching consequences, according to many academic institutions and professional societies.The cuts would reduce federal funding to University of Pennsylvania by nearly $250 million per year and “have a profoundly negative impact on
    about 2 months ago
    healio.com

    FDA approves therapies for colorectal cancer, mantle cell lymphoma

    The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for treatment of patients with mantle cell lymphoma.
    3 months ago
    healio.com

    Association launches initiative to support firefighters affected by...

    The Association of Cancer Care Centers launched a fundraising initiative to support the Firefighter Cancer Support Network.The association will match donations up to $10,000.
    3 months ago
    healio.com

    Combination extends survival vs. standard first-line therapy for ad...

    A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung cancer, according to the agents’ manufacturer.The OS benefit with amivantamab-vmjw (Rybrevant, Janssen) and lazertinib (Lazcluze; Janssen) is expected to exceed 1 year, according to a press release issued by Johnson & Johnson.
    3 months ago
    healio.com

    Talking about β€˜taboo’ topics strengthens provider-patient relations...

    Extensive research published or presented in the past year highlights the value of clear provider-patient communication about topics that may be uncomfortable to discuss.These subjects range from AI to advanced care planning, cannabis to costs of care, and survivorship challenges to the impact of cancer and its treatments on sexual health.
    3 months ago
    healio.com

    Top stories in oncology 2024: Cannabis, vaping increase cancer risk

    As 2024 comes to a close, Healio is pleased to present our most widely read oncology and hematology content from the past 12 months.We hope you enjoy this look back at what you and your colleagues considered some of the most compelling research breakthroughs or treatment advances over the past year.
    3 months ago
    healio.com

    FDA approves Unloxcyt for advanced cutaneous squamous cell carcinoma

    The FDA approved cosibelimab-ipdl for the treatment of certain patients with cutaneous squamous cell carcinoma.The indication applies to adults with metastatic or locally advanced disease who are not candidates for curative surgery or curative radiation.
    4 months ago
    healio.com

    FDA approves therapies for lung, pancreatic cancers

    The FDA approved two oncology therapies for treatment of certain patients with lung cancer or pancreatic cancer.The agency approved durvalumab (Imfinzi, AstraZeneca) for use by adults with limited-stage small cell lung cancer whose disease had not progressed after concurrent platinum-based chemotherapy and radiation therapy.
    4 months ago
    healio.com

    FDA approves Ziihera for advanced HER2-positive biliary tract cancer

    The FDA granted accelerated approval to zanidatamab-hrii for treatment of adults with previously treated unresectable or metastatic HER2-positive biliary tract cancer. Zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals) is a HER2-targeted bispecific antibody administered via IV.
    4 months ago
    healio.com

    Triplet regimen extends OS in relapsed or refractory multiple myeloma

    A triplet regimen extended OS compared with the current standard of care for patients with relapsed or refractory multiple myeloma, according to a topline data announcement.Patients with multiple myeloma often become refractory to first-line triplet or quadruplet therapy regimens, creating a need for effective second- or later-line treatments.
    5 months ago